Secondary hyperparathyroidism from inadequate calcium absorption in the gut, is the underlying pathophysiology for rachitic changes in hereditary vitamin D-resistant rickets (HVDRR). We describe a novel use of Cinacalcet to treat a child with HVDRR in whom conventional modes of therapy had to be discontinued. Cinacalcet therapy with high-dose oral calcium effectively normalized the metabolic abnormalities and bone condition. The relative ease of administration of the calcimimetic as a once- or twice-daily oral preparation, compared with traditional intravenous calcium administration, should encourage its move to the frontline of treatment of the disorder.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Cinacalcet; Familial Hypophosphatemic Rickets; Humans; Infant; Male; Naphthalenes; Treatment Outcome
Srivastava, T., Alon, U. S. Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28, 992-996 (2013).
Biochemical Phenomena, Metabolism, and Nutrition Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Nephrology Commons, Pediatrics Commons, Pharmaceutical Preparations Commons